Condition: Neisseria Meningitidis Serogroup B · Sponsor: Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)
A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.
This description comes directly from the study's public registry record.
Project Manager · （+86）021-50360201 · clic@delonixbio.com
Always discuss trial participation with your own doctor first.
| Linear Early Phase Limited | Perth, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07395739